TOP-FLOR: Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab. (clinicaltrials.gov) - Oct 17, 2026 - P2 | N=40 | Active, not recruiting | Sponsor: Olivia Newton-John Cancer Research Institute | Trial completion date: Jun 2027 ➔ Jun 2029 | Trial primary completion date: Jan 2027 ➔ Jan 2028
Trial completion date • Trial primary completion date • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology • CD20
|